Abstract
Corrigendum to “A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone”: [ESMO Open 8 (2023) 102033]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have